The U.S. Food and Drug Administration (FDA) issued a warning on Thursday, stating that numerous units of counterfeit Ozempic have been seized. While the agency continues to investigate, it cautions that some fraudulent units of the diabetes drug, produced by Novo Nordisk, may still be circulating in the market.

To determine the quality and safety of the seized products, both Novo Nordisk and the FDA are conducting tests. It is important to note that these counterfeit products also feature counterfeit needles, which pose a serious risk of infection due to the inability to confirm their sterility.

Patients are strongly advised to examine all received products and cross-reference the lot and serial numbers listed on the FDA's website with those associated with the counterfeit products.

Regrettably, at least five adverse events have been reported in connection with these counterfeit products. These incidents align with typical side effects of genuine Ozempic, such as nausea and vomiting.

In response to this concerning issue, Novo Nordisk released a statement expressing their dedication to combatting counterfeit products and unlawful activities within the market. They have vowed to collaborate with the FDA in order to identify any potential imitation products in the United States.

Patient safety remains of utmost importance, and both the FDA and Novo Nordisk are taking swift action to address this critical situation.

Alphabet Inc. Cl A Shares Rally on Positive Trading Session

Increases in Holdings

Leave A Reply

Your email address will not be published. Required fields are marked *

Related posts

Concerns Arise Over Expectations for AMD's Data Center Unit
News

Concerns Arise Over Expectations for AMD's Data Center Unit

Semiconductor analysts raise concerns about AMD's data center unit's high expectations, following Intel's shortfalls in...

Bank of America Stock Rises
News

Bank of America Stock Rises

Bank of America Corp. (BAC) stock rises 0.98% on Friday, marking the second consecutive day of gains. It is still $6.04...

NYC Mourns Loss of Owl Flaco
News

NYC Mourns Loss of Owl Flaco

New York City mourns the sudden loss of Flaco, an iconic owl known for his resilience in the urban jungle. Investigation...

BridgeBio Pharma Inc. Announces $250 Million PIPE Equity Offering
News

BridgeBio Pharma Inc. Announces $250 Million PIPE Equity Offering

BridgeBio Pharma Inc. experiences 3.8% surge in stock price after announcing $250 million PIPE equity offering. The offe...